It takes GUTS to be BOLD: A look at the new biotech tickers As the public markets heat up in biotech, industry insiders expect a small drumbeat of IPOs later this spring, and that means a new set of stock tickers to track. Next up is BOLD, the proposed name of Boundless Bio’s Nasdaq stock. Using that name would mark a return for the ticker, which freed up after Astellas bought Audentes Therapeutics for $3 billion in 2019. Boundless is expected to make its Wall Street debut in the coming weeks after unveiling plans to go public earlier this month. Unlock this article instantly by becoming a free subscriber. You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
This content was originally published here.
